Pharma company Cipla Limited announced the appointment of Venkata Sai Mungara as Global Head – Supply Chain of the company, with effect from April 1, 2024. Venkata Sai Mungara is an accomplished leader with over two and half decades of rich experience in the supply chain domain out of which over 10 years of his…
Cipla Limited (Cipla) announced that it has agreed to acquire additional stake for INR 25.90 cr. in digital tech company GoApptiv Private Limited (hereinafter referred as “Goapptiv”) and post completion of the deal, Cipla’s total stake in GoApptiv will increase to 22.02% on a fully diluted basis. The investment will be made in equity shares…
Cipla Limited announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel in India. The product is indicated for the treatment of ICE due to Buerger’s disease and atherosclerotic peripheral arterial disease. It is the first allogeneic cell therapy to…
Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for COVID-19 treatment options…